The Phase II Triple Negative Breast Cancer study is going to start recruiting any day now. They have to be near done the manufacturing aspect of the vaccine. Announcement on that study commencement is imminent IMHO. The media release will highlight the Phase I results and why it was so striking (it should). I expect we will see renewed interest in this small company trickle in to this message board. Followed up with lots of attention once a Ovarian combination with CI is announced. The idea of keeping recurrence at bay in two cancers that have no further treatment options is huge. It should bring National Media coverage, at minimum "Good Morning America" like segment. They're impressive as a monotherapy to cover but the fact that they will get to test efficacy as a combination therapy will be seen as further validation of their technology. Big Pharma collaboration is destined to make some retail investor consider buying this stock.
And then the DoD study, that's bound to show up on the NCT site within a few months (possibly before, as they received the grant last year); again a bunch of new eyes on TPIV. And then a new IND for the HER-2 vaccine which combines Knutson's latest patent to the former one, along with their Polystart patent.
And then they will become grant recipients again (which they'll qualify for upon Orphan designation and Moon shot monies). Scientific papers which they promised on Polystart, and on HER-2 study which ended. And then updates at scientific conferences later in the year on open labels, namely FRa. Remember they will have Ovarian & TNBC Phase I long term follow-up data in a few months (July) as the final analysis is due then on survival. We will get to see why the FRa was Fast Tracked in the first place, presented in scientific abstracts. And then we should hear updates on phase II enrollment, at least the smaller studies. That will hopefully propel momentum to the upside, add to their valuation and ultimately help them to up-list.
I'm obviously am optimistic. Anyway, the upcoming catalyst on TPIV are bigger to me than an first interim analysis to "proceed". But, yes GALE was beat up over past mistakes so it should bounce back a bunch too.
News 
Market Data 
Discover 
